BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 33851429)

  • 1. Dopamine agonists for preventing ovarian hyperstimulation syndrome.
    Tang H; Mourad SM; Wang A; Zhai SD; Hart RJ
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD008605. PubMed ID: 33851429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine agonists for preventing ovarian hyperstimulation syndrome.
    Tang H; Mourad S; Zhai SD; Hart RJ
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD008605. PubMed ID: 27901279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cabergoline for preventing ovarian hyperstimulation syndrome.
    Tang H; Hunter T; Hu Y; Zhai SD; Sheng X; Hart RJ
    Cochrane Database Syst Rev; 2012 Feb; (2):CD008605. PubMed ID: 22336848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome.
    D'Angelo A; Amso NN; Hassan R
    Cochrane Database Syst Rev; 2017 May; 5(5):CD002811. PubMed ID: 28535578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome.
    Tso LO; Costello MF; Albuquerque LET; Andriolo RB; Macedo CR
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD006105. PubMed ID: 33347618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Volume expanders for the prevention of ovarian hyperstimulation syndrome.
    Youssef MA; Mourad S
    Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD001302. PubMed ID: 27577848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF/ICSI cycles.
    Mochtar MH; Danhof NA; Ayeleke RO; Van der Veen F; van Wely M
    Cochrane Database Syst Rev; 2017 May; 5(5):CD005070. PubMed ID: 28537052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fresh versus frozen embryo transfers in assisted reproduction.
    Zaat T; Zagers M; Mol F; Goddijn M; van Wely M; Mastenbroek S
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD011184. PubMed ID: 33539543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI).
    Lensen SF; Wilkinson J; Leijdekkers JA; La Marca A; Mol BWJ; Marjoribanks J; Torrance H; Broekmans FJ
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD012693. PubMed ID: 29388198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology.
    Youssef MA; Van der Veen F; Al-Inany HG; Mochtar MH; Griesinger G; Nagi Mohesen M; Aboulfoutouh I; van Wely M
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD008046. PubMed ID: 25358904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral contraceptive pill, progestogen or oestrogen pretreatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques.
    Farquhar C; Rombauts L; Kremer JA; Lethaby A; Ayeleke RO
    Cochrane Database Syst Rev; 2017 May; 5(5):CD006109. PubMed ID: 28540977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral medications including clomiphene citrate or aromatase inhibitors with gonadotropins for controlled ovarian stimulation in women undergoing in vitro fertilisation.
    Kamath MS; Maheshwari A; Bhattacharya S; Lor KY; Gibreel A
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD008528. PubMed ID: 29096046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI).
    Ngwenya O; Lensen SF; Vail A; Mol BWJ; Broekmans FJ; Wilkinson J
    Cochrane Database Syst Rev; 2024 Jan; 1(1):CD012693. PubMed ID: 38174816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endometrial injection of embryo culture supernatant for subfertile women in assisted reproduction.
    Siristatidis CS; Sertedaki E; Karageorgiou V; Vaidakis D
    Cochrane Database Syst Rev; 2020 Aug; 8(8):CD013063. PubMed ID: 32797689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology.
    Al-Inany HG; Youssef MA; Ayeleke RO; Brown J; Lam WS; Broekmans FJ
    Cochrane Database Syst Rev; 2016 Apr; 4(4):CD001750. PubMed ID: 27126581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous platelet-rich plasma for assisted reproduction.
    Vaidakis D; Papapanou M; Siristatidis CS
    Cochrane Database Syst Rev; 2024 Apr; 4(4):CD013875. PubMed ID: 38682756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring of stimulated cycles in assisted reproduction (IVF and ICSI).
    Kwan I; Bhattacharya S; Woolner A
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD005289. PubMed ID: 33844275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgens (dehydroepiandrosterone or testosterone) for women undergoing assisted reproduction.
    Naik S; Lepine S; Nagels HE; Siristatidis CS; Kroon B; McDowell S
    Cochrane Database Syst Rev; 2024 Jun; 6(6):CD009749. PubMed ID: 38837771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gonadotrophins for ovulation induction in women with polycystic ovary syndrome.
    Weiss NS; Kostova E; Nahuis M; Mol BWJ; van der Veen F; van Wely M
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD010290. PubMed ID: 30648738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fresh versus frozen embryo transfers in assisted reproduction.
    Wong KM; van Wely M; Mol F; Repping S; Mastenbroek S
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011184. PubMed ID: 28349510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.